BioHeal Therapeutics: Innovating Simplified Wound Care for Chronic Wounds and Severe Burns

BioHeal Therapeutics is a leading global regenerative medicine company dedicated to simplifying the application of amnion wound care products for chronic wounds and severe burns. Traditional amnion sheet products often tear or fold during application, causing frustration for wound care specialists. Our BioHeal Hydrogel technology overcomes these challenges, allowing for easy application and supporting natural wound healing efficiently, saving both time and money. (Not available in the US).

BioHeal Therapeutics has secured an exclusive worldwide licensing agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM), affiliated with Wake Forest School of Medicine. This agreement grants us development and commercialization rights for innovative amnion-derived technologies proven to support wound closure, protection, healing, and repair of chronic wounds and severe burns.

We are rapidly expanding our portfolio with patented regenerative treatment products designed to improve patient outcomes, reduce pain, and lower healthcare costs. Founded by industry veterans Bruce Anderson and Steve Anderson, BioHeal Therapeutics brings over 50 years of global experience in developing, manufacturing, processing, and commercializing more than 20 implantable human cardiovascular and orthopedic tissues, as well as Class II and III medical devices.

Headquartered in suburban Atlanta, Georgia, BioHeal Therapeutics was formed in Florida and remains committed to delivering innovative, proprietary, and patented medical devices. Our solutions are designed for easy application, supporting effective wound closure and promoting healthy tissue, ultimately improving patients' lives.

Meet the Team

Steve Anderson1939-2023

Mr. Anderson was Chairman of the Board and co-founder of BIOHEAL THERAPEUTICS, LLC from 2017 until his passing in 2023. Mr. Anderson was co-founder, President/CEO of CryoLife, Inc. (now Artivion) from 1984 - 2015. He took the company public on Nasdaq in 1994 and moved it to the NYSE in 1997. Prior to that he was Executive Vice President of Intermedics, Inc. (now Boston Scientific) from 1976 to 1983. From 1973 to 1976 he was President of US Operations for Biotronik, Inc. He was the top sales representative and region manager for Medtronic from 1968 - 1973. He was an entrepreneur, pioneer and leader in the medical device industry. CryoLife cardiac tissues revolutionized pediatric cardiac reconstructive surgery and helped save the lives of thousands of children. CryoLife vascular tissues helped save the limbs of thousands of adults with peripheral vascular disease. CryoLife products have been used in 80 different countries. He was one of a handful of people in medical devices to start a company, take it public and run day to day operations as President/CEO for over 30 years. He was a graduate of the University of Minnesota at Minneapolis.

Bruce Anderson

President & CEO

Bruce Anderson, President/CEO. Mr. Anderson has more than 20 years global experience developing, manufacturing, processing and commercializing BioGlue the number one surgical adhesive used in cardiovascular surgery in the world,  over 20 implantable human cardiovascular and orthopedic tissues as well as Class II and III medical devices. Elected in 2014, Mr. Anderson has served as Vice President of US Sales and Global Marketing for CryoLife (now Artivion). During this time, he led a team of over 120 people, including all worldwide product marketing functions for the company. Prior to that, he was elected and has served as Vice President, US Sales and Marketing in 2008. From 2002 to 2007, he was Director of US Sales, leading the sales team to double digit growth. CryoLife's preserved human tissues and surgical adhesives have been implanted in and improved the lives of about 2 million people. He is a graduate of the University of South Florida at Tampa.